NASDAQ$VRNA
Verona Pharma plc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported first quarter financial results and provided a corporate update.
Verona Pharma reported its Q1 2024 financial results, highlighting the upcoming PDUFA target action date for ensifentrine and ongoing preparations for a potential US launch. The company also strengthened its balance sheet through a new financing agreement.
- PDUFA target action date for ensifentrine is June 26, 2024, with potential US launch in Q3 2024.
- Finalizing key launch preparations including sales force deployment strategy, pricing, distribution and patient services, healthcare professional and patient engagement plans.
- Strengthened balance sheet with access to up to $650 million in addition to existing cash of $255 million.
- Net loss was $25.8 million for the first quarter ended March 31, 2024
Headline financials
Revenue & EPS history
Verona Pharma · Revenue · Quarterly
$0
Forward guidance
Verona Pharma is focused on the potential launch of ensifentrine in the US, preparing for Phase 2 clinical trials, and highlighting COPD burden through disease awareness campaigns.
Tailwinds
- Potential US launch of ensifentrine in Q3 2024.
- Finalizing key launch preparations.
- Presenting posters at the American Thoracic Society International Conference (“ATS”) 2024.
- Initiating a Phase 2 clinical trial assessing the safety and efficacy of a fixed-dose combination formulation of ensifentrine and glycopyrrolate
- Initiating a Phase 2 clinical trial to assess the efficacy and safety of nebulized ensifentrine in patients with non-cystic fibrosis bronchiectasis
Headwinds
- Lengthy and expensive process of clinical drug development, which has an uncertain outcome
- Serious adverse, undesirable or unacceptable side effects associated with ensifentrine, which could adversely affect our ability to develop or commercialize ensifentrine
- Economic, political, regulatory and other risks involved with international operations
- Reliance of our business on the success of ensifentrine
- Reliance on third parties, including clinical research organizations, clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize ensifentrine
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q1 2024
+3.3%
Avg return
Earnings day
+7.2%
Avg return
5 days after
+5.6%
Avg return
30 days after
48%
12 / 25 earnings
Positive
+56.8%
Q2 2022
Best reaction
-14.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | -0.0% | -0.1% | +0.9% | |
| Q1 2025 | +6.4% | +5.6% | +12.5% | |
| Q4 2024 | +5.7% | +6.4% | +1.5% | |
| Q3 2024 | +9.7% | +10.2% | +14.0% | |
| Q2 2024 | +15.8% | +36.5% | +35.1% | |
| Q1 2024 | -0.2% | -6.8% | -18.4% | |
| Q4 2023 | +5.4% | -1.1% | -6.4% | |
| Q3 2023 | +7.6% | — | — | |
| Q2 2023 | -3.4% | — | — | |
| Q1 2023 | +7.1% | — | — | |
| Q4 2022 | -8.5% | — | — | |
| Q3 2022 | -5.8% | — | — | |
| Q2 2022 | +56.8% | — | — | |
| Q1 2022 | +3.8% | — | — | |
| Q4 2021 | -1.1% | — | — | |
| Q3 2021 | -1.7% | — | — | |
| Q2 2021 | +3.9% | — | — | |
| Q1 2021 | -4.4% | — | — | |
| Q4 2020 | -0.1% | — | — | |
| Q2 2020 | +10.3% | — | — | |
| Q4 2019 | -14.7% | — | — | |
| Q4 2018 | -3.3% | — | — | |
| Q3 2018 | +2.1% | — | — | |
| Q4 2017 | -3.5% | — | — | |
| Q3 2017 | -4.2% | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro